Rhythm reported over 700 MCVRI start forms for acquired hypothalamic obesity and said it remains self-sustaining without external capital. The company committed $350 million over four years to reduce BIVA-Mellagon royalties to 1% and plans a Prader-Willi study in 2027.
RYTM · Rhythm Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Rhythm Pharmaceuticals said its AHO launch is maintaining a steady pace into the fourth quarter, it has $750 million of debt capacity with $250 million expected to be drawn, and it aims to start a Prader-Willi trial in early Q3.
Rhythm Pharmaceuticals reported global net product sales of $92.1 million in the third quarter, up 29% sequentially. More than 700 patient start forms were received, and the acquired HO therapy launched in Japan on October 14th.
Rhythm reported third-quarter IMCIVREE global sales of $92.1 million, up 29% sequentially. A term loan provides up to $750 million, while an amended bivamelagon license requires $350 million in fixed payments over four years.
Rhythm Pharmaceuticals reported IMCIVREE revenue of $92.1 million, up 29% sequentially, and more than 700 patient start forms. Net loss attributable to common stockholders was $(42.4) million; a five-year term loan provides access to up to $750 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 3, 2026TL;DR. Rhythm delivered 29% sequential product-revenue growth, sustained U.S. launch momentum, launched IMCIVREE in Japan, advanced bivamelagon into pivotal development, reduced the portfolio royalty to 1%, and expects at least 24 months of operating funding. The company remained loss-making as R&D and SG&A increased, while Japan's initial two-week supply restriction may constrain launch uptake.
- + Q3 global IMCIVREE product revenue reached $92.1 million, increasing 29% sequentially.
- + The U.S. acquired-HO launch exceeded 700 patient start forms from more than 500 prescribers.
- + The commercial launch of IMCIVREE for acquired HO in Japan began on October 13, 2026.
- + Bivamelagon is advancing into pivotal trials in both acquired HO and Prader-Willi syndrome.
- + The amended bivamelagon license reduces the MC4R portfolio royalty to 1% of net product revenue.
- + Management expects available cash and investments to fund planned operations for at least 24 months.
- − Rhythm reported a Q3 net loss attributable to common stockholders of $42.4 million, or $0.61 per share.
- − Q3 R&D expenses increased year over year, primarily because of CMC activity, clinical-trial and personnel costs, and a congenital hyperinsulinism milestone.
- − Q3 SG&A expenses increased year over year, primarily because of higher personnel costs tied to expanded operations.
- − Japan's first-year launch restricts prescriptions to two-week supply and requires hospital consultations every two weeks.
- − Rhythm must pay LG Chem $350 million in fixed payments over four years, beginning with $70 million due 15 days from closing.
- − Cash, cash equivalents and short-term investments declined from $388.9 million at December 31, 2025 to approximately $320.9 million at September 30, 2026.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net product revenue from global sales of IMCIVREE | $92.13M | FY2026 Q3 | +79.6% |
|
|
|||
| Adult Endocrinologist share of prescribers | 43% | Between FDA approval on March 19, 2026 and June 30, 2026 | — |
| Cash, cash equivalents and short-term investments | $330.9M | as of June 30, 2026 | — |
| Commercial covered lives with positive policies | 35% | Between FDA approval on March 19, 2026 and June 30, 2026 | — |
| Ex-U.S. revenue | $20.3M | second quarter of 2026 | — |
| Ex-U.S. share of product revenue | 28% | the second quarter of 2026 filing | — |
| Increase in number of patients globally on reimbursed therapy | 20% | Q2 2026 | — |
| Mean BMI reduction from baseline with RM-718 (n=7) at 16 weeks | 11.6% | after 16 weeks of treatment | — |
| Medicaid covered lives with positive policies | 25% | Between FDA approval on March 19, 2026 and June 30, 2026 | — |
| Patient start forms since FDA approval | 400 | as of June 30, 2026 | — |
| Pediatric Endocrinologist share of prescribers | 37% | Between FDA approval on March 19, 2026 and June 30, 2026 | — |
| Prescribers activated | 65% | Between FDA approval on March 19, 2026 and June 30, 2026 | — |
| Repeat aHO prescribers | 20% | Between FDA approval on March 19, 2026 and June 30, 2026 | — |
| revenue generated from a single customer in the United States | 72% | the three months ended June 30, 2026 filing | — |
| Sequential increase in IMCIVREE global sales | 19% | Q2 2026 | — |
| Share of prescriptions from priority accounts | 25% | Between FDA approval on March 19, 2026 and June 30, 2026 | — |
| Share of product revenue generated from sales to patients in the United States | 72% | the three months ended June 30, 2026 filing | +9.1% |
|
|
|||
| Share of Q2 2026 revenue from U.S. | 72% | Q2 2026 | — |
| U.S. revenue | $51M | second quarter of 2026 | — |
| Unique prescribers | 300 | Between FDA approval on March 19, 2026 and June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RYTM
this stock
Rhythm Pharmaceuticals, Inc.
|
$8.25B | +11.2% | +45.8% | — | 16.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 11, 2026
- This year
- 29
Rhythm reported over 700 MCVRI start forms for acquired hypothalamic obesity and said it remains self-sustaining without external capital. The company committed $350 million over four years to reduce BIVA-Mellagon royalties to 1% and plans a Prader-Willi study in 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RYTM | +6.1% | +34.3% | +34.8% | +28.6% | +11.2% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +10.0% | +39.9% | +38.3% | +32.0% | +4.1% |